{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rhuFab+V2+%28ranibizumab%29&page=4",
    "query": {
      "intervention": "rhuFab V2 (ranibizumab)",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 263,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rhuFab+V2+%28ranibizumab%29&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rhuFab+V2+%28ranibizumab%29&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T13:26:58.281Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02127684",
      "title": "Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Persistent Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maturi, Raj K., M.D., P.C.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2014-07-30",
      "last_synced_at": "2026-10-14T13:26:58.281Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02127684"
    },
    {
      "nct_id": "NCT00769145",
      "title": "Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 5,
      "start_date": "2008-10",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2017-07-11",
      "last_synced_at": "2026-10-14T13:26:58.281Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00769145"
    },
    {
      "nct_id": "NCT00676559",
      "title": "Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Efalizumab",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-04",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2016-08-26",
      "last_synced_at": "2026-10-14T13:26:58.281Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • San Diego, California • Torrance, California + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Bangor",
          "state": "Maine"
        },
        {
          "city": "South Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00676559"
    },
    {
      "nct_id": "NCT00831350",
      "title": "Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinal Vein Occlusion",
        "Posterior Vitreous Detachment"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barnes Retina Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2009-04",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2017-10-30",
      "last_synced_at": "2026-10-14T13:26:58.281Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00831350"
    },
    {
      "nct_id": "NCT01157065",
      "title": "Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Exudative Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "AL-78898A",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2011-06",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-10-14T13:26:58.281Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01157065"
    },
    {
      "nct_id": "NCT02107131",
      "title": "Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Intravitreal ranibizumab 0.3mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "California Retina Consultants",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-03-13",
      "completion_date": "2017-05-15",
      "has_results": true,
      "last_update_posted_date": "2018-12-19",
      "last_synced_at": "2026-10-14T13:26:58.281Z",
      "location_count": 6,
      "location_summary": "Bakersfield, California • Oxnard, California • Palmdale, California + 3 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Palmdale",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02107131"
    },
    {
      "nct_id": "NCT00500344",
      "title": "CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Lucentis (ranibizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2007-07",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2018-05-03",
      "last_synced_at": "2026-10-14T13:26:58.281Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00500344"
    },
    {
      "nct_id": "NCT01205035",
      "title": "High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinal Diseases",
        "Telangiectasis"
      ],
      "interventions": [
        {
          "name": "ranibizumab 2.0mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Center of Northern Colorado, P.C.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2010-10",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2015-04-10",
      "last_synced_at": "2026-10-14T13:26:58.281Z",
      "location_count": 1,
      "location_summary": "Fort Collins, Colorado",
      "locations": [
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01205035"
    },
    {
      "nct_id": "NCT00473642",
      "title": "Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Age-Related Maculopathy",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Verteporfin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oklahoma State University Center for Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2007-05",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-10-14T13:26:58.281Z",
      "location_count": 1,
      "location_summary": "Tulsa, Oklahoma",
      "locations": [
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00473642"
    },
    {
      "nct_id": "NCT01115556",
      "title": "A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vitreous -Retina- Macula Consultants of New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2010-05",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2018-05-03",
      "last_synced_at": "2026-10-14T13:26:58.281Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01115556"
    }
  ]
}